Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities

NEW YORK, July 17, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities http://www.reportlinker.com/p0935310/Pharmaceutical-Pricing-and-Reimbursement-in-Oncology---Payer-Pressure-to-Justify-Premium-Pricing-of-Novel-Agents-Pushing-Companies-to-Risk-Sharing-Modalities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

Summary

GBI Research, leading business intelligence provider, has released its latest research report, entitled "Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities". It provides a comprehensive overview of the healthcare system, and the pricing and reimbursement processes in the top seven countries of the world, with a detailed analysis of the different regulatory mechanisms used in these countries. The report closely scrutinizes the major pharmaceutical changes and oncology-related pricing and reimbursement in these countries in the recent past and their impact in the near future. The countries analyzed in the report are the US, the top five European countries of the UK, France, Italy, Germany and Spain; and Japan.

Cancer is considered to be one of the most feared diseases, a cure for which has so far eluded researchers all over the world. However, new lines of therapeutics Vascular Endothelial Growth Factor (VEGF) inhibitors and Epidermal Growth Factor Receptor (EGFR) inhibitors are expected to make a significant impact on patient survival. However, progress in patient survival and other benefits are accompanied by premium prices, which has necessitated the creation of several agencies responsible for making decisions pertaining to pricing and reimbursement for cancer drugs in many countries of the world in order to contain costs related to cancer treatment. The report on "Pharmaceutical Pricing and Reimbursement in Oncology " delves into these recent changes in pricing and reimbursement mechanisms that are often targeted at expensive cancer drugs.

Scope

- Detailed study of the healthcare systems and roles of the key players in the respective pharmaceutical systems of the top seven countries of the world – the US, the UK, France, Germany, Italy, Spain and Japan.

- Analysis of the major pricing and reimbursement mechanisms in each country.

- Key trends that follow from the recent changes brought about in pricing and reimbursement mechanisms.

- Analysis of the possible major challenges brought about by the enactment of changes in the pricing and reimbursement scene in the countries covered in the report.

- Particular focus on pricing and reimbursement in oncology.

Reasons to buy

- Build an understanding of the oncology-related key pricing and reimbursement mechanisms in the top seven countries of the world.

- Optimize your investment through identification and understanding of the changes in oncology drugs' regulatory mechanisms and in the pricing and reimbursement scenario for the countries covered in the report.

- Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in the pricing and reimbursement scene for the countries covered.

Table of Contents1 Table of Contents1 Table of Contents 51.1 List of Tables 61.2 List of Figures 72 Pricing and Reimbursement in Oncology - Introduction 83 Pricing and Reimbursement in Oncology - Overview 93.1 Development of Oncology Drugs 123.2 Market Access and the Role of Health Economics in Cancer Drugs 133.2.1 Regulation of Cancer Drugs in Europe 133.2.2 Hospital Budgets and Patient Access to Drugs 133.2.3 Payers Managing Influx of New Therapies through Innovative Strategies 143.2.4 Risk Sharing Agreements in the US Vis-à-vis Europe 153.3 Difference in Reimbursement for Oncology Drugs between the US and Europe 153.4 Rationalizing Costs in the US 154 Pricing and Reimbursement in Oncology - The US 164.1 Introduction 164.2 Regulatory Bodies 174.3 Trends 184.3.1 Oncology Practice and Expenditure in the US 184.3.2 Expenditure on Cancer Care Until 2020 - Costs May Increase by 27% from 2010 184.3.3 Reimbursement of Prescription Drugs - Oncology Falls under Tier Four 244.3.4 Strategies to Control Healthcare Spending 244.3.5 Oral Targeted Chemotherapeutics are the Next Paradigm in Cancer Care 254.3.6 Reimbursement Issues in Oral Chemotherapeutics 254.3.7 Oral Chemotherapy Parity Act 265 Pricing and Reimbursement in Oncology - Top Five Countries of Europe 275.1 Italy 275.1.1 Introduction 275.1.2 Regulatory Bodies 285.1.3 Trends 295.2 Spain 315.2.1 Introduction 315.2.2 Regulatory Bodies 315.2.3 Trends 325.3 Germany 345.3.1 Introduction 345.3.2 Regulatory Bodies 355.3.3 Trends 375.4 France 395.4.1 Introduction 395.4.2 Regulatory Bodies 415.4.3 Trends 435.5 The UK 475.5.1 Introduction 475.5.2 Regulatory Bodies 485.5.3 Trends 506 Pricing and Reimbursement in Oncology - Japan 556.1 Introduction 556.2 Regulatory Bodies 576.3 Trends 586.3.1 Fee Changes for the Elderly in Japan Suffering from Cancer 586.3.2 Off-label Uses of Drugs Agreed to be Given Conditional Reimbursement 586.3.3 Changes to Japan's Pricing System for Market Leading Drugs 586.3.4 New Medicines Included in NHI List Including Eisai's Breast Cancer Drug Halaven 587 Pricing and Reimbursement in Oncology - Appendix 607.1 Market Definitions 607.2 Abbreviations 607.3 Sources 637.4 Research Methodology 647.4.1 Introduction 647.4.2 Regulatory Bodies 647.4.3 Key Trends 647.5 Contact Us 657.6 Disclaimer 65

List of Tables

1.1 List of TablesTable 1: Pricing and Reimbursement in Oncology, Age Standardized Cancer Incidence, Top Seven Countries, 2008 10Table 2: Pricing and Reimbursement in Oncology, Age Standardized Cancer Mortality, Top Seven Countries, 2008 11Table 3: Pricing and Reimbursement in Oncology, Examples of Innovative Reimbursement Agreements 14Table 4: Pricing and Reimbursement in Oncology, the US, Expenditure for Cancer Care in the Top Five Sites ($bn), 2010 and 2020 20Table 5: Pricing and Reimbursement in Oncology, the US, Expenditure for Cancer Care in Other Sites ($bn), 2010 and 2020 21Table 6: Pricing and Reimbursement in Oncology, Average Retail Coinsurance Rates, the US, By Tier (%), 2009 24Table 7: Pricing and Reimbursement in Oncology, Public Pharmaceutical Expenditure, Pharmacies, 2010-2011 33Table 8: Pricing and Reimbursement in Oncology, Germany, Healthcare Expenditure by Financing Agent, $ per inhabitant, 2007, 2008, 2009 35Table 9: Pricing and Reimbursement in Oncology, France, Types of Treatment and their Reimbursement Levels 40Table 10: Pricing and Reimbursement in Oncology, Market Entry Restrictions for Cancer Drugs, the UK 51Table 11: Pricing and Reimbursement in Oncology, the UK, General Price Changes (%), 2009-2013 53Table 12: Pricing and Reimbursement in Oncology, Healthcare Expenditure, Japan, 2009 55Table 13: Pricing and Reimbursement in Oncology, Trend in Revision Rates of Reimbursement Prices, Japan, 1992-2008 56Table 14: Pricing and Reimbursement in Oncology, Change in Premiums, Japan, 2002-2008 57Table 15: Pricing and Reimbursement in Oncology, List of Drugs Introduced to NHI, Japan, 2011 59

List of Figures

1.2 List of FiguresFigure 1: Pricing and Reimbursement in Oncology, Diseased Population in the Top Seven Countries for Major Types of Cancer (millions), 2010 9Figure 2: Pricing and Reimbursement in Oncology, Age Standardized Cancer Incidence, Top Seven Countries, 2008 10Figure 3: Pricing and Reimbursement in Oncology, Age Standardized Cancer Mortality, Top Seven Countries, 2008 11Figure 4: Pricing and Reimbursement in Oncology, the US, Total Healthcare Expenditure vs. Out-of-Pocket Expenditure (%), 2009 17Figure 5: Pricing and Reimbursement in Oncology, the US, Expenditure for Cancer Care ($bn), 2010 and 2020 19Figure 6: Pricing and Reimbursement in Oncology, the US, Expenditure for Cancer Care in the Top Five Indications ($bn), 2010 and 2020 20Figure 7: Pricing and Reimbursement in Oncology, the US, Estimated Cancer Cases, By Sites, Men (%), 2011 22Figure 8: Pricing and Reimbursement in Oncology, the US, Estimated Cancer Cases, By Sites, Women (%), 2011 23Figure 9: Pricing and Reimbursement in Oncology, Total Per-capita Expenditure on Pharmaceuticals, Top Five Countries of Europe and the US, $PPP, 1990-2009 27Figure 10: Pricing and Reimbursement in Oncology, NHS and Private Composition of Pharmaceutical Expenditure, Italy, %, 2009 28Figure 11: Pricing and Reimbursement in Oncology, Public Pharmaceutical Expenditure, Pharmacies, Growth Rates (%), 2010-2011 32Figure 12: Pricing and Reimbursement in Oncology, Germany, Healthcare Expenditure by Financing Agent, $ per inhabitant, 2007, 2008, 2009 34Figure 13: Pricing and Reimbursement in Oncology, Germany, Structural Reforms by AMNOG, 2011 37Figure 14: Pricing and Reimbursement in Oncology, European Counties, the US and Japan, Total Healthcare Expenditure vs. Out-of-Pocket Expenditure, 2009 39Figure 15: Pricing and Reimbursement in Oncology, Regulatory Bodies and Functions, France 41Figure 16: Pricing and Reimbursement in Oncology, HTA to P&R Decisions, France 42Figure 17: Pricing and Reimbursement in Oncology, Public and Private Expenditure on Health as % of Total Expenditure on Health, 2009 47Figure 18: Pricing and Reimbursement in Oncology, the UK, NHS Expenditure on Medicines ($bn) vs. NHS Medicines Cost Per Capita ($), 2000-2009 49Figure 19: Pricing and Reimbursement in Oncology, Life Expectancy at Age 65 Years, Males and Females, Japan, 2009 56

Companies Mentioned

To order this report: General Medicine and Specialty Medicine Industry: Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities

More Market Research Report

Check our Industry Analysis and Insights

__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker